SUD responder status

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)

Adolescents court-mandated to treatment had greater odds of achieving a 50% reduction in substance use but lower odds of completing treatment, compared to voluntary participants.

Effect: mixed; OR=3.71 (SUD responder); OR=0.40 (treatment completer); CI: 95% CI: 1.26 to 10.89 (SUD responder); 95% CI: 0.17 to 0.94 (treatment completer)